The phase of the phase BIIB0592 trial of the human-derived IgG1 monoclonal antibody reached the main end of the study.

today, Biogencompany(http://announced that its humanized IgG1 monoclonal antibody BIIB059, in the treatment of skin lupus (CLE) and systemic lupus (SLE) patients in the stage 2test(http://LILAC reached the main end of the studyAbout BIIB059
BIIBIB059 is a humanized IgG1 monoclonal antibody targeting blood dendritic cell antigen 2 (BDCA2) and is currently being developed for the treatment of CLE and SLE patientsBDCA2 is a receptor that is expressed only on human immunocellular plasma protrusion cells (pDc), which can reduce the production of inflammatory cytokines, including type I interferon (IFN-I), and play an important regulatory role in the pathological mechanism of lupusA total of 264 patients participated in a phase 2 clinical study called LILAC, a two-blind, placebo-controlled groupThe results showed that at week 16, BIIB059 significantly improved the area of skin lupus and severity index activity (CLASI-A) in CLE patients compared to the baseline, reaching the main endpoint of the trialOf these, the CLASI-A scores of patients treated with 50 mg, 150 mg and 450 mg BIIB059 were reduced by 40.9%, 48.0% and 42.5%, respectively, compared with 14.5% in the placebo groupThe LILAC study also reached the main end of the study for the treatment of SLE patients, with BIIB059 significantly reducing disease activity in SLE patients at 24 weeks of treatment compared to baselinesDetailed trial data from the study will be available at the
of the http:// at future medical meetings